Soligenix Showcases Innovative Therapies for Rare Diseases at BIO Investment & Growth Summit
- Soligenix presents advancements in therapies for rare diseases at the BIO Investment & Growth Summit in Miami Beach.
- The company’s HyBryte™ therapy for CTCL achieves significant Phase 3 study success, aiming for global market introduction.
- Soligenix explores vaccines through ThermoVax® technology, backed by support from NIAID and DTRA for public health initiatives.
Soligenix Advances New Therapies for Rare and Infectious Diseases
Soligenix, Inc., a biopharmaceutical company focused on innovative treatments for rare diseases, announces that CEO Dr. Christopher J. Schaber will present at the upcoming BIO Investment & Growth Summit taking place in Miami Beach, Florida on March 2-3. This event serves as a platform for the company to outline its recent advancements in specialized therapeutics and to explore potential collaboration opportunities. As Soligenix prepares for future commercialization efforts, the developments in their pipeline could enhance their position within the industry.
At the forefront of Soligenix's initiatives is HyBryte™ (SGX301), a groundbreaking photodynamic therapy designed specifically for cutaneous T-cell lymphoma (CTCL). The company recently concluded a successful second Phase 3 study, which is a significant milestone as they aim to introduce this novel treatment to the global market. The advancement not only signifies progress for the company but also provides a potential new therapeutic option for patients afflicted with CTCL, addressing a notable gap in the treatment landscape. Alongside HyBryte™, Soligenix is also exploring the expansion of its synthetic hypericin (SGX302) to target psoriasis, indicating a commitment to addressing a range of dermatological conditions.
Additionally, Soligenix is making strides in inflammatory disease interventions with their first-in-class innate defense regulator, dusquetide (SGX942), which targets oral mucositis in patients undergoing head and neck cancer treatments. The company is also advancing SGX945, addressing Behçet's Disease. Furthermore, their Public Health Solutions segment is actively working on vaccines utilizing their proprietary ThermoVax® technology, with projects underway for ricin toxin (RiVax®), filoviruses, and COVID-19 (CiVax™). The backing of organizations such as the National Institute of Allergy and Infectious Diseases (NIAID) and the Defense Threat Reduction Agency (DTRA) underscores the support for these critical initiatives aimed at enhancing public health.
The BIO Investment & Growth Summit represents a timely opportunity for Soligenix to engage with potential partners interested in novel therapeutics and vaccine development. The focus on rare diseases and infectious agents positions the company as a key player in biopharmaceutical advancements. Soligenix encourages relevant stakeholders to schedule one-on-one meetings with management during the conference or connect through email for collaboration discussions. For further details about their pipeline and corporate developments, interested parties can visit Soligenix's website or follow their updates on social media.
